Rsv Financial News

Pfizer, Moderna and Novavax all plan to bring boosters to the market this fall. Pfizer expects to win Food and Drug Administration approval in August, with vaccinations starting in September. Novavax said it expects to get clearance and ship doses in September, and Moderna said it is waiting for approval.

As Canadians continue to enjoy the last bit of summer’s sun-soaked days, doctors say they are bracing for a potential “tripledemic” of influenza, respiratory syncytial virus (RSV) and COVID-19, signalling the imminent arrival of respiratory flu season.

U.S. regulators have approved the first RSV vaccine for pregnant women to protect their newborns

Respiratory Syncytial Virus (RSV) in their babies. The Pfizer shot, which was already approved for use in older adults, has now been greenlighted for use as a single injection from 32 through 36 weeks of pregnancy, to protect infants from birth through six months, a statement by the Food and Drug Administration said. It is the latest in a succession of medicines recently approved against the common microbe, which causes tens of thousands of hospitalizations among infants and the elderly in the United States every year, according to official estimates. Researchers have targeted an RSV vaccine since the 1960s, but the spate of shots that are emerging now were made possible thanks to a scientific breakthrough a decade ago. «RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalization,» said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. «This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease.» The approval follows a clinical trial involving some 7,000 pregnant women, which showed Pfizer's vaccine, called Abrysvo, reduced severe disease caused by RSV by 82 percent in babies from 0-3 months, and 69 percent from 0-6 months. Abrysvo was previously approved by the FDA for adults aged 60 and over, as was another vaccine by drugmaker GSK, called Arexvy. While RSV most often causes mild, cold-like symptoms in infants and young children, it can also lead to more serious outcomes such as pneumonia and bronchiolitis. An estimated 58,000-80,000 children younger than five years are hospitalized due to RSV infection, according to

Pfizer, Moderna and Novavax all plan to bring boosters to the market this fall. Pfizer expects to win Food and Drug Administration approval in August, with vaccinations starting in September. Novavax said it expects to get clearance and ship doses in September, and Moderna said it is waiting for approval.

U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus

(Reuters) -The European Union's health regulator on Friday backed authorization of Pfizer (NYSE:PFE)'s vaccine for respiratory syncytial virus (RSV) for use in babies and older adults.